VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 24, 2017

Primary Completion Date

December 20, 2017

Study Completion Date

December 20, 2017

Conditions

Bacterial Infections

Interventions

DRUG

VNRX-5133

β-lactamase inhibitor

DRUG

VNRX-5022

Approved β-lactam antibiotic

DRUG

Metronidazole

Approved antibiotic and antiprotozoal medication

DRUG

Placebo

Placebo (matching VNRX-5133 + VNRX-5022)

Trial Locations (1)

PRAHS, Lenexa

All Listed Sponsors

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Venatorx Pharmaceuticals, Inc.

INDUSTRY

NCT03332732 - VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter